Best Ways to Manage Cisplatin Exposure After Mesothelioma Treatment
This excerpt sheds light on mesothelioma, a challenging cancer affecting the linings of the lungs, abdomen, or heart due to exposure to asbestos.
Doctors often combine various treatments to aid mesothelioma patients, one of which is Hyperthermic Intrathoracic Chemotherapy (HITOC). This method delivers cisplatin directly to the cancer site.
A recent study delved
into post-HITOC safety measures, particularly examining how cisplatin exits the
body via fluids like blood, urine, and lung secretions. Samples from five HITOC
patients were collected pre and post-treatment, along with subsequent days,
using ICP-MS to measure cisplatin levels.
Best Ways to Manage Cisplatin Exposure After Mesothelioma Treatment
Following HITOC,
cisplatin levels notably surged in body fluids but decreased over the next nine
days. Around 59% of cisplatin was eliminated through urine within 48 hourspost-HITOC.
While cisplatin levels
in HITOC patients' body fluids were lower than in those receiving intravenous
medicine, a substantial amount remained. Thus, post-HITOC patient care demands
safety precautions, potentially involving protective clothing and gear for
healthcare workers to prevent cisplatin exposure.
This study offers
critical insights into cisplatin elimination post-HITOC, aiding doctors and
healthcare providers in implementing necessary safety measures for everyone's
well-being during mesothelioma treatment.
Source:
Larisch C, Markowiak T, Ried M, Nowak D, Hofmann HS, Rakete S. The Excretion of Cisplatin after Hyperthermic Intrathoracic Chemotherapy. Cancers (Basel). 2023;15(19):4872. Published 2023 Oct 6. doi:10.3390/cancers15194872. Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10571901/
Comments
Post a Comment